cagrilintide and semaglutide Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Co-formulation of Semaglutide and Cagrilintide

Reversible hyperpigmentation of skin and nails with white hair due to vitamin B12 deficiency

Administration of L-carnitine in combination with orlistat or sibutramine has been shown to improve anthropomorphic, glycemic, and insulin parameters compared with L-carnitine monotherapy in patients with type 2 diabetes mellitus

Menon, S.G

In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4(+) and CD8(+) T-cell epitopes for cancer immunotherapy

Danne T, Cariou B, Banks P et al (2018) HbA 1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study

Especially not one that tamps down something as ancient as hunger